Latest Capital Raises News

Mantle Minerals has agreed to sell its Mt Roe gold project subsidiary for $13.5 million, marking a pivotal step in its growth strategy. The company also secured a government drilling grant for its Mt Berghaus project and raised $250,000 to support ongoing operations.

Patrys Limited has launched a fully underwritten entitlement offer to raise approximately $1.77 million, aiming to accelerate development and commercial activities around its deoxymabs program.

Mindax Limited has secured an option to acquire Norton Goldfields’ 35% stake in the Mt Forrest magnetite project, potentially gaining full ownership of a major iron ore asset in Western Australia’s Mid-West region.

Macarthur Minerals has clarified the timing of its entitlement offer, confirming the securities issue date as 7 August 2025 with ASX quotation expected the following day. The company also reaffirmed its substantial iron ore resources at Lake Giles, maintaining investor confidence ahead of the capital raise.

Agrimin Limited progresses its Mackay Potash Project with ongoing strategic review and strong stakeholder backing, while securing $2.5 million through equity placement and completing the Tali Resources IPO.

Sayona Mining has updated its timetable for the merger with Piedmont Lithium, conditional placement, and share consolidation, aiming to simplify and speed up the process pending shareholder approval.

Sayona Mining has updated its timetable for the merger with Piedmont Lithium, conditional placement, and share consolidation, aiming to simplify and speed up the process pending shareholder approval.

Rimfire Pacific Mining is advancing its position as a leading scandium explorer in Australia’s Fifield district, with plans for new Mineral Resource Estimates and a $3.5 million capital raise to fund drilling and exploration. Joint ventures with Golden Plains Resources have been reinstated, underpinning a strategic push in a critical mineral market facing supply constraints.

Rimfire Pacific Mining Limited has had its trading suspension lifted immediately following the release of its capital raising results, signaling renewed market activity.

Amplia Therapeutics has launched a $27.5 million capital raising to advance its lead drug Narmafotinib, a promising FAK inhibitor showing superior efficacy in pancreatic cancer trials. The funds will support ongoing and new clinical studies, positioning the company for pivotal regulatory milestones.

Amplia Therapeutics has successfully raised A$25 million through an institutional placement and launched a A$2.5 million Share Purchase Plan to fund pivotal clinical trials of its lead drug narmafotinib. The capital injection positions the company to advance key pancreatic and ovarian cancer studies into 2027.

IperionX has successfully commissioned its Virginia titanium manufacturing campus, secured a substantial U.S. Department of Defense contract, and raised $46 million to fast-track production expansion through 2030.